Slide 1: Driving growth with winning assets
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices
Slide 2: Q2 2022 Results
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Q2 2022 Results Play to Win July 28, 2022
Slide 3: Forward-looking statements
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Forward-looking statements This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward- looking statements are statements tha
Slide 4: Agenda
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Agenda 01 Driving growth with winning assets Paul Hudson 02 Business update Bill Sibold, Thomas Triomphe, Olivier Charmeil & Julie Van Ongevalle 03 Financial performance and outlook Jean-Baptiste de Chat
Slide 5: Driving growth with winning assets
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Driving growth with winning assets
Slide 6: Growth drivers delivered strong Q2 performance, +8.1%
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Growth drivers delivered strong Q2 performance, +8.1% Specialty Care Vaccines GenMed Specialty Care €4.1bn €1.2bn €3.6bn Dupixent® nearly €2bn in sales +21.6% +8.7% -4.1% Vaccines Core assets up on pande
Slide 7: Dupixent - Now annualizing almost €8bn
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Dupixent - Now annualizing almost €8bn ® 5 years after launch, growing >40% Over 450k patients treated Biologics treatment eligible population around 7 million AD EoE 6m-5 yrs Asthma 12+ yrs U.S. ~150k e
Slide 8: Play to Win: Major proof points of execution on 6-year plan
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Play to Win: Major proof points of execution on 6-year plan Today 2020-2022 2023-2025+ ü 8 consecutive quarters of growth • Maximize Dupixent® megabrand ü 320bps BOI margin • Increase investment in pipel
Slide 9: R&D transformation delivering on strategy
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices R&D transformation delivering on strategy 2020 H1 2022 Dupixent® accelerated Dupixent® approved in development across Type 2 4 disease indications in the U.S., inflammatory diseases 3 with positive pedia
Slide 10: Driving growth with winning assets Business update Financial performance
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices
Slide 11: Nirsevimab, all infant protection against RSV
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Nirsevimab, all infant protection against RSV Pivotal trial results published in NEJM1 74.5%2 77.3%3 efficacy compared reduction of RSV-associated to placebo hospitalizations Filed in Europe, decision ex
Slide 12: Positive data against Omicron with Beta-containing COVID-19 vaccine
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Positive data against Omicron with Beta-containing COVID-19 vaccine Phase 3 efficacy study with bivalent vaccine Primary series SAN-GSK next-gen vaccine First to report successful efficacy against Omicro
Slide 13: Global Health Unit
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Global Health Unit “We view Sanofi as one of Treatments available the innovators in the industry. at accessible prices In our view, one of Sanofi's leading differentiators is its creation of a non-profit
Slide 14: Business update
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Business update Q2 2022
Slide 15: Specialty Care performance €4.1bn sales
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Specialty Care performance €4.1bn sales +21.6% Q2 2022 Dupixent® Oncology Dupixent® Outstanding Q2 performance in global markets and €263m €1,963m 4th d
Slide 16: Dupixent continues to deliver outstanding performance with a strong Q2 step-up
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Dupixent continues to deliver outstanding performance ® with a strong Q2 step-up Global Dupixent® sales (€m) Performance highlights in Q2 Ex-U.S. U.S. I
Slide 17: Dupixent 5th positive pediatric pivotal trial across three Type 2 inflammatory diseases
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Dupixent 5th positive pediatric pivotal trial across three Type 2 ® inflammatory diseases reinforcing established efficacy and safety Expanding to pedia
Slide 18: Efanesoctocog alfa was well tolerated and prophylaxis provided highly effective protection against bleeds
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Efanesoctocog alfa was well tolerated and prophylaxis provided highly effective protection against bleeds FDA Primary endpoint met Breakthrough Therapy
Slide 19: Vaccines performance €1.2bn sales
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Vaccines performance €1.2bn sales +8.7% Q2 2022 Travel & Endemic Polio Pertussis Hib Travel and Boosters vaccines €145m €589m accelerated recovery acros
Slide 20: Sanofi influenza vaccines raise the bar by providing protection beyond flu in adults 65+
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Sanofi influenza vaccines raise the bar by providing protection beyond flu in adults 65+ 1 CDC preferential recommendation2 for adults 65+: Fluzone® Hig
Slide 21: GenMed performance €3.6bn sales
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare GenMed performance €3.6bn sales -4.1% Q2 2022 Core Core assets1 on track with ambition to assets reach 60% of total GenMed sales by 2025 €1,611m Robust
Slide 22: GenMed: Q2 2022 core assets performance
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare GenMed: Q2 2022 core assets performance € millions -10.9% Q2 2021 Q2 2022 +2.4% +0.0% +35.3% 367 337 267 247 234 247 222 +2.5% +47.91% 150 +4.3% 79 91 7
Slide 23: Expanding affordable access for underserved communities
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Expanding affordable access for underserved communities Valyou insulin program in the U.S. Continued commitment to ensure affordability by lowering out-
Slide 24: CHC: Consistent growth now in line with market
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare CHC: Consistent growth now in line with market Delivering on strategy Growth (MAT, in %) +16.5% +14.0% Grow priority brands above market growth +15.4% +
Slide 25: CHC performance €1.3bn sales
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare CHC performance €1.3bn sales +9.1% Q2 2022 Digestive Wellness Pain Care Q2 organic growth +10.5% €336m €304m +9.3% +5.8% 5th consecutive growth quarter
Slide 26: Financial performance
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Financial performance Q2 2022
Slide 27: Q2 P&L
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Q2 P&L €m Q2 2022 Q2 2021 % Change (CER) Net Sales 10,116 8,744 +8.1% Other revenues 626 301 +85.0% Gross profit 7,493 6,187 +12.2% Gross margin % 74.1%1 70.8%1 R&D (1,658) (1,396) +12.8% SG&A (2,574) (2
Slide 28: Transformation driving strong H1 financial performance indicators
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Transformation driving strong H1 financial performance indicators H1 2022 H1 2021 Change1 Sales €19.8bn €17.3bn +8.4% Gross margin 74.1%2 71.5%2 +2.1pp R&D spend €3.1bn €2.7bn +13.4% BOI margin 29.4% 28.
Slide 29: Driving growth with winning assets Business update Financial performance
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices
Slide 30: Reinvesting an incremental €0.5bn in growth over one year
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Reinvesting an incremental €0.5bn in growth over one year +€0.5bn 0.2 -1.1 1.5 38.0 -0.8 38.5 -0.5 0.8 -0.5 Cumulative R&D prioritization R&D efficiencies R&D priority S&M S&M S&M Others Cumulative OPEX
Slide 31: Outlook H2 2022
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Outlook H2 2022
Slide 32: Anticipated H2 drivers relevant to FY 2022 BOI margin target
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Anticipated H2 drivers relevant to FY 2022 BOI margin target BOI margin evolution Business dynamics in H2 • Dupixent growth 30% • Stable Specialty Care growth • Capital gains 29.4% from divestitures • Eu
Slide 33: Upgraded 2022 FY guidance
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Upgraded 2022 FY guidance BOI margin EPS growth 30% around 15% growth at CER Approximately +7.5% to +8.5% currency impact1 Barring unforseen events. 1. Based on July 2022 average rates. 33 Investor Relat
Slide 34: Q&A session
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Q&A session
Slide 35: R&D appendices
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations R&D appendices
Slide 36: Expected R&D milestones in 2022
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Expected R&D milestones in 2022 H1 2022 H2 2022 Status as of Q2 Dupixent® EoE U.S./EU regulatory submissions Approved U.S./
Slide 37: R&D Pipeline Phase III & Registration
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations R&D Pipeline Phase III & Registration Phase III Registration Name Description Indication Name Description Indication Dupixe
Slide 38: R&D Pipeline – Phase II
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations R&D Pipeline – Phase II Phase II Name Description Indication Name Description Indication R Kevzara®A Anti-IL-6 mAb Polyarti
Slide 39: R&D Pipeline – Phase I
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations R&D Pipeline – Phase I Phase I Name Description Indication SAR441566 Oral TNF inhibitor Inflammatory indications SAR444656I
Slide 40: Expected submission timelines
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Expected submission timelines 2022 2023 2024 2025 and beyond Dupixent®A Dupixent®A tusamitamab Nexviazyme® efanesoctocog al
Slide 41: Amcenestrant: Addressing large unmet need in 1L and adjuvant ER+ breast cancer
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Amcenestrant: Addressing large unmet need in 1L and adjuvant ER+ breast cancer Main Planned Population Trial (n) comparator
Slide 42: Financial appendices
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Financial appendices
Slide 43: Q2 sales and EPS
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Q2 sales and EPS Currency impact Company sales Business EPS €661m +0.07 +0.12 +0.04 €341m -0.15 -0.12 -0.15 -0.11 0 0 225 -
Slide 44: Net debt evolution in H1 2022
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Net debt evolution in H1 20221 12,190 € millions 340 9,983 4,168 -3,735 615 1,360 -541 Net Debt FCF before Proceeds Asset R
Slide 45: 2022 currency sensitivity and Q2 2022 currency exposure
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations 2022 currency sensitivity and Q2 2022 currency exposure 2022 Business EPS currency sensitivity Currency exposure on Q2 2022
Slide 46: 2022 business outlook
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations 2022 business outlook Sales Specialty Care Vaccines Growth driven by Dupixent®, Record flu season sales P&L N&I slightly do
Slide 47: Sanofi accounting of Antibody License and Collaboration Agreement with Regeneron
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Sanofi accounting of Antibody License and Collaboration Agreement with Regeneron 1 Last updated July 2022 U.S. Ex-U.S. Net
Slide 48: Sanofi Libtayo accounting pursuant to Immuno-Oncology License and Collaboration Agreement
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Sanofi Libtayo® accounting pursuant to Immuno-Oncology License and Collaboration Agreement with Regeneron 1 Applicable befo
Slide 49: Sanofi Libtayo accounting pursuant to Amended and Restated Agreement
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Sanofi Libtayo® accounting pursuant to Amended and Restated Immuno-Oncology License and Collaboration Agreement with Regene
Slide 50: Main product sales
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Main product sales Q2 2022 sales (€m) Growth Dupixent 1,963 43.4% Lantus 600 -12.1% Aubagio 526 -2.2% Lovenox 337 -10.9% Pl
Slide 51: ESG appendices
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations ESG appendices
Slide 52: Sanofi ESG Q2 achievements
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Sanofi ESG Q2 achievements Affordable access R&D for unmet needs Global Health Unit #Patients treated Rare disease vials do
Slide 53: Sanofi ESG Q2 achievements
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Sanofi ESG Q2 achievements Planet care In and beyond the workplace Blister-free syringe vaccines Scope 1 & 2 Diverse Senior
Slide 54: Sanofi ESG ratings
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Sanofi ESG ratings Rating agencies SCORE Climate 22 86/100 74/100 A Change: A B 4.2/5 3.47/5 92% 62/100 Medium risk Water:
Slide 55: Collaborations
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Collaborations Ref Name Developed in collaboration with… A Dupixent® Regeneron itepekimab Libtayo® Kevzara® B efanesoctocog
Slide 56: Abbreviations
Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Abbreviations Ab Antibody FGFR3 Fibroblast Growth Factor Receptor 3 PN Prurigo Nodularis ABR Annualized Bleed Rate GAA Acid